Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modified erythropoietin polypeptides and uses thereof for treatment

A technology of erythropoietin and peptide polypeptides, which is applied in the fields of erythropoietin, extracellular fluid diseases, medical preparations containing active ingredients, etc., can solve the problem of highly variable, difficult, and expensive preparation of glycosylated therapeutic proteins and other problems to achieve the effect of increasing stability and increasing protein half-life

Active Publication Date: 2013-12-25
韩诺生物制约株式会社
View PDF60 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally, many therapeutic proteins are glycosylated, and making glycosylated therapeutic proteins is expensive, highly variable, and difficult to perform

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified erythropoietin polypeptides and uses thereof for treatment
  • Modified erythropoietin polypeptides and uses thereof for treatment
  • Modified erythropoietin polypeptides and uses thereof for treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0696] Cloning and production of EPO mutants

[0697] 1. Cloning of cDNA encoding EPO and insertion into mammalian expression vector

[0698] Using the following primers using standard techniques known in the art from Human clone IDRG001720 (from ResGen ORF Expression Positive Collection - Cat #H-K1000, Invitrogen; sequence carried in mammalian expression plasmid pcDNA3.1 / GS, Invitrogen, SEQ ID NO: 230) by polymerase chain reaction (PCR) Amplify the nucleotide sequence including the coding sequence of human erythropoietin (SEQ ID NO: 229):

[0699] EPO BamHI forward primer: 5'-GGGAATTCCATATGGGGGTGCACGAATGTCCTGCCTGG-3' (SEQ ID NO: 231) and

[0700] EPO NdeI reverse primer: 5'-CGGGATCCTCATCTGTCCCCTGTCCTGCAGGCCTCCC-3' (SEQ ID NO: 232).

[0701] The amplified sequence human erythropoietin cDNA sequence was cloned into pTOPO-TA vector (Invitrogen) to generate plasmid pTOPO-TA-hEPO. The sequence of the EPO cDNA was checked by automated DNA sequencing. The pTOPO-TA-hEPO plasmid...

Embodiment 2

[0716] Production and Yield Determination of Natural and Modified Human EPO Polypeptides (Proteins) in Mammalian Cells

[0717] Chinese hamster ovary (CHO) cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum (FCS). The day before transfection, 5×10 per well 5 Density of cells in DMEM containing 10% FCS (without antibiotics) at 37°C in 7% CO 2 The CHO cells were plated in 6-well plates in a humidified atmosphere of components to achieve 50-90% confluency a few days after transfection.

[0718] CHO cells were transfected with 2 μg of EPO mutant DNA using Perfectin reagent (Ozyme) according to the manufacturer's instructions. After transfection the cells were plated in Reduced serum medium (Invitrogen) at 37°C in 7% CO 2 Components were incubated for 4 hours in a humid atmosphere. After incubation, the transfection medium was replaced with fresh 1 ml DMEM medium containing 1% FCS. Cell supernatants were collected after 96 hours, aliquoted...

Embodiment 3

[0721] Determination of specific activity of human EPO by TF-1 proliferation assay

[0722] Proliferation assays were performed on aliquots sampled at different time points of protease degradation kinetics in the human erythroleukemia cell line TF-1 bioassay to determine the residual proliferative activity (EC 50 ).

[0723] In RPMI 1640 medium (Invitrogen) supplemented with 10% FCS, 2mM L-glutamine, and 2ng / ml human recombinant GM-CSF, at 37°C in 7% CO 2 / 95% air composition in a humid atmosphere, at T175 (175cm 2 ) polystyrene tissue culture flasks and split twice weekly. Twenty-four hours before use in proliferation assays, cells were washed twice in ice-cold PBS and resuspended in GM-CSF-free RPMI medium supplemented with 2 mM glutamine and 10% FCS for 16 hours .

[0724] TF1 cells were divided into 4 × 10 per well 4 Cells were plated in 96-well plates in 70 [mu]l of GM-CSF-free RPMI medium supplemented with 2 mM glutamine and 10% FCS. Aliquots were two-fold serially...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other modified therapeutic polypeptides are modified to exhibit different physical properties and activities than the corresponding unmodified EPO polypeptides and other unmodified therapeutic polypeptides. Nucleic acid molecules encoding these polypeptides are also provided. Also provided are methods of using the polypeptides for therapy or diagnosis.

Description

[0001] related application [0002] Claiming priority to U.S. Provisional Application 60 / 861,615, filed November 28, 2006, entitled "MODIFIED ERYTHROPOIETINPOLYPEPTIDES AND USES THEREOF," to Thierry Guyon, Giles Borrelly, Xavier Gallet, Lila Drittanti, and Manuel Vega . [0003] This application is related to a corresponding US application, Internal Number 17109-021001 / 931, entitled "MODIFIED ERYTHROPOIETIN POLYPEPTIDES AND USESTHEREOF", filed by Thierry Guyon, Giles Borrelly, Xavier Gallet, LilaDrittanti and Manuel Vega. This application is related to U.S. Application 11 / 176,830, filed July 6, 2005, entitled "RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES," by applicants Rene Gantier, Thierry Guyon, Manuel Vega, and Lila Drittanti, Its disclosure is U.S. application US 2006-0020116, which is a continuation of U.S. application 10 / 658,834, filed September 8, 2003, entitled "RATIONAL EVOLUTION OF CYTOKINES FOR HIGHERSTABILI...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/18C07K14/505
CPCA61K33/26A61K38/193C07K14/505A61K38/00A61K31/555A61K45/06A61P7/06A61P9/02A61P9/10A61P21/02A61P25/00A61P25/06A61P25/08A61P25/16A61P25/18A61P25/22A61P25/28A61P25/32A61P27/02A61P29/00Y02A50/30A61K2300/00A61K38/19A61K38/20A61K38/21
Inventor T·居永G·博雷利X·加莱L·德里坦蒂M·韦加
Owner 韩诺生物制约株式会社
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com